Form 4: ATNF Director Shoemaker's Stock & Option Grant

180 Life Sciences Corp. director Stephen H. Shoemaker reported beneficial ownership of common stock and a new grant of 181,422 non-qualified stock options.

Summary

• Stephen H. Shoemaker, a Director and 10% Owner of 180 Life Sciences Corp. (ATNF), reported his beneficial ownership.
• He directly owns 132,439 shares of Common Stock.
• On August 8, 2025, he was granted 181,422 non-qualified stock options with an exercise price of $3.01 per share.
• The options expire on August 8, 2035, and were granted under the 2025 Second Supplemental Option Plan.
• These options were issued in consideration for services rendered and agreed to be rendered as a director.
• While the options vested immediately, they are not exercisable until stockholder approval of the 2025 Second Supplemental Option Plan is received.
• If stockholder approval is not obtained by August 8, 2026, the options will be cancelled.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The grant of options to a director is a positive for aligning incentives, but the contingency on stockholder approval introduces a minor uncertainty. It's a routine compensation disclosure rather than a major operational or financial announcement.

Positives

• Grant of 181,422 non-qualified stock options to a director aligns management incentives with shareholder value.
• The options were issued for services rendered, indicating continued commitment from a key director.

Negatives

• Exercisability of the 181,422 stock options is contingent on future stockholder approval of the 2025 Second Supplemental Option Plan.
• Failure to obtain stockholder approval by August 8, 2026, will result in the cancellation of the options.

Risks

• The 181,422 stock options granted to the director are subject to cancellation if stockholder approval for the 2025 Second Supplemental Option Plan is not received by August 8, 2026.

Future Outlook

The future exercisability of the 181,422 stock options is dependent on obtaining stockholder approval for the 2025 Second Supplemental Option Plan by August 8, 2026.

Management Comments

• The options were granted under the 2025 Second Supplemental Option Plan of the Issuer.
• The options vested immediately, but are not exercisable until stockholder approval of the 2025 Second Supplemental Option Plan is received.
• If stockholder approval is not received prior to August 8, 2026, the options will be cancelled.
• Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a director of the Issuer.

Industry Context

This filing is a standard disclosure of director compensation and beneficial ownership, common across publicly traded companies. It reflects a company's use of equity incentives to compensate and retain key personnel, a common practice in the biotechnology and life sciences sector to align long-term interests.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a common practice in the biotechnology and pharmaceutical industries, similar to companies like Moderna (MRNA) or Pfizer (PFE), which frequently use equity to incentivize leadership.
• The contingency of stockholder approval for option plans is a standard corporate governance practice, ensuring alignment with shareholder interests, comparable to practices seen at companies like Gilead Sciences (GILD) or Amgen (AMGN) when implementing new equity incentive plans.
• The exercise price of $3.01 for the options is specific to ATNF's stock valuation at the time of grant and would need comparison to peer companies' option grants at similar market caps or development stages to assess its relative attractiveness.

Corporate Governance

Related Party Transactions

• Grant of 181,422 non-qualified stock options to Stephen H. Shoemaker, a Director and 10% Owner, in consideration for services rendered to the Issuer.

Stakeholder Impact

• Shareholders: Potential dilution if options are exercised, but also potential for increased director alignment with shareholder interests. Requires future approval of the option plan.
• Management/Directors: Stephen H. Shoemaker receives additional equity compensation, incentivizing his continued service and performance.

Next Steps

• The company needs to obtain stockholder approval for the 2025 Second Supplemental Option Plan.

Key Dates

Recommendation

This Form 4 filing is a routine disclosure of director compensation and beneficial ownership. It does not contain new financial results, strategic shifts, or material operational updates that would warrant a change in investment recommendation. The grant of options is a standard practice to align director incentives, but its exercisability is contingent on future stockholder approval, which is a minor uncertainty. Therefore, a "hold" recommendation is appropriate as the filing provides no new information to alter the fundamental investment thesis.

Keywords

180 Life Sciences Corp., ATNF, Stephen H. Shoemaker, SEC Form 4, Stock Options, Director Compensation, Beneficial Ownership, Equity Grant, Corporate Governance